ClinicalTrials.gov Identifier: NCT05496517
The study will comprise at least 8 international cancer centers. Data of patients,
newly diagnosed with OC between January 2010 and December 2016, will be
retrospectively collected. Therefore, a follow-up of at least 5 years would be granted. All women who will be diagnosed with primary ovarian cancer at any stage, of all histological types and grades eligible for the study. All contributing centers should acquire institutional review board (IRB) approval prior to data collection.